Tuberculosis Treatment Drugs Market By Disease Type (Active Tuberculosis, Latent Tuberculosis), By Therapy Type (First Line Therapy, Second Line Therapy), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
The Tuberculosis Treatment Drugs Market valued for $1,929.96 million in 2021 and is estimated to reach $3,243.90 million by 2031, exhibiting a CAGR of 5.3% from 2022 to 2031.
Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs, but can also affect other parts of the body such as the kidneys, bones, and brain. TB is transmitted through the air when an infected person coughs, sneezes, or talks. It is an airborne disease, which means that it can easily spread from person to person through the inhalation of infected droplets. The diagnosis of TB is typically based on a combination of medical history, physical examination, chest X-ray, and laboratory tests such as sputum microscopy and culture. Moreover, various first line drugs such as isoniazid, rifampin, ethambutol, and others and second line drugs such as cyclosterine, ethioamide, capreomycin, and others are approved and used to treat tuberculosis.
The driving factor for tuberculosis treatment drugs market is rise in prevalence of tuberculosis cases. For instance, according to report of Centers for Disease Control and Prevention (CDC) 2022, it was stated that 7,882 million cases of TB were reported in 2021, i.e. 9.4% increase in TB cases. Thus, rise in prevalence of tuberculosis cases results in high demand for drugs which is expected to drive the growth of market. Further, increase in number of pipeline medications for treating tuberculosis disease that is anticipated to receive regulatory approval in the upcoming years; will drive the growth during the forecast period.
Furthermore, rise in initiatives by non-government & government organizations to increase awareness about the TB disease and available treatments among the patients through different programs and campaigns is predicted to boost the growth of the market. In addition, rise in adoption of advanced technologies to diagnose tuberculosis disease and awareness about the importance of early diagnosis is anticipated to boost the market growth. Moreover, many key players have adopted key strategies such as collaboration, agreement, or alliance to increase their market presence in the global tuberculosis treatment drugs market, which is expected to drive the growth of the market.
However, factors such as major side effects associated with tuberculosis drugs may restrain the growth of tuberculosis treatment drugs market. In addition, increase in extensive drug resistance can hamper the growth of the market.
Moreover, rise in demand for novel therapeutics for treating tuberculosis and strong presence of pipeline molecules along with rise in regulatory approvals for new therapeutics is expected to offer lucrative opportunities to key players of market.
The global tuberculosis treatment drugs market is segmented into disease type, therapy type, distribution channel, and region. On the basis of disease type, the market is categorized into active tuberculosis and latent tuberculosis. As per therapy type, the market is categorized into first line therapy and second line therapy. According to distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).
Major key players that operate in the global tuberculosis treatment drugs market are Lupin, Sanofi, Pfizer Inc., Fresenius SE & Co. KGaA (Fresenius Kabi), Johnson & Johnson, Teva Pharmaceuticals, Novartis AG, ANI Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., and Macleods Pharmaceuticals Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tuberculosis treatment drugs market analysis from 2021 to 2031 to identify the prevailing tuberculosis treatment drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the tuberculosis treatment drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global tuberculosis treatment drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Type
Active Tuberculosis
Latent Tuberculosis
By Therapy Type
First Line Therapy
Second Line Therapy
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
LAMEA
Latin America
Middle East And Africa
Key Market Players
Lupin
Sanofi
Pfizer Inc.
FRESENIUS SE & Co. KGaA (Fresenius Kabi)
Johnson & Johnson
Novartis AG
Macleods Pharmaceuticals Ltd.
ANI Pharmaceuticals, Inc.
Otsuka Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in R&D for tuberculosis drugs
- 3.4.1.2. Growing initiatives from government organizations for tuberculosis awareness
- 3.4.1.3. Rise in adoption of combinational therapy
- 3.4.2. Restraints
- 3.4.2.1. Adverse effects of Anti-Tuberculosis Drugs
- 3.4.2.2. Stringent Regulatory Guidelines for product approval
- 3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Active Tuberculosis
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Latent Tuberculosis
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- CHAPTER 5: TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. First Line Therapy
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Second Line Therapy
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Drug Stores and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: TUBERCULOSIS TREATMENT DRUGS MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Disease Type
- 7.2.3. Market size and forecast, by Therapy Type
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Disease Type
- 7.2.5.1.3. Market size and forecast, by Therapy Type
- 7.2.5.1.4. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Disease Type
- 7.2.5.2.3. Market size and forecast, by Therapy Type
- 7.2.5.2.4. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Disease Type
- 7.2.5.3.3. Market size and forecast, by Therapy Type
- 7.2.5.3.4. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Disease Type
- 7.3.3. Market size and forecast, by Therapy Type
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Disease Type
- 7.3.5.1.3. Market size and forecast, by Therapy Type
- 7.3.5.1.4. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Disease Type
- 7.3.5.2.3. Market size and forecast, by Therapy Type
- 7.3.5.2.4. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Disease Type
- 7.3.5.3.3. Market size and forecast, by Therapy Type
- 7.3.5.3.4. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Disease Type
- 7.3.5.4.3. Market size and forecast, by Therapy Type
- 7.3.5.4.4. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Disease Type
- 7.3.5.5.3. Market size and forecast, by Therapy Type
- 7.3.5.5.4. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Disease Type
- 7.3.5.6.3. Market size and forecast, by Therapy Type
- 7.3.5.6.4. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Disease Type
- 7.4.3. Market size and forecast, by Therapy Type
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Disease Type
- 7.4.5.1.3. Market size and forecast, by Therapy Type
- 7.4.5.1.4. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Disease Type
- 7.4.5.2.3. Market size and forecast, by Therapy Type
- 7.4.5.2.4. Market size and forecast, by Distribution Channel
- 7.4.5.3. India
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Disease Type
- 7.4.5.3.3. Market size and forecast, by Therapy Type
- 7.4.5.3.4. Market size and forecast, by Distribution Channel
- 7.4.5.4. Rest of Asia-Pacific
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Disease Type
- 7.4.5.4.3. Market size and forecast, by Therapy Type
- 7.4.5.4.4. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Disease Type
- 7.5.3. Market size and forecast, by Therapy Type
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Latin America
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Disease Type
- 7.5.5.1.3. Market size and forecast, by Therapy Type
- 7.5.5.1.4. Market size and forecast, by Distribution Channel
- 7.5.5.2. Middle East And Africa
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Disease Type
- 7.5.5.2.3. Market size and forecast, by Therapy Type
- 7.5.5.2.4. Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2021
- CHAPTER 9: COMPANY PROFILES
- 9.1. Lupin
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Macleods Pharmaceuticals Ltd.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.3. Sanofi
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. Otsuka Pharmaceutical Co., Ltd.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Key strategic moves and developments
- 9.5. Pfizer Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. FRESENIUS SE & Co. KGaA (Fresenius Kabi)
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Johnson & Johnson
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Teva Pharmaceutical Industries Ltd.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Novartis AG
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. ANI Pharmaceuticals, Inc.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 02. TUBERCULOSIS TREATMENT DRUGS MARKET FOR ACTIVE TUBERCULOSIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 03. TUBERCULOSIS TREATMENT DRUGS MARKET FOR LATENT TUBERCULOSIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 04. GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 05. TUBERCULOSIS TREATMENT DRUGS MARKET FOR FIRST LINE THERAPY, BY REGION, 2021-2031 ($MILLION)
- TABLE 06. TUBERCULOSIS TREATMENT DRUGS MARKET FOR SECOND LINE THERAPY, BY REGION, 2021-2031 ($MILLION)
- TABLE 07. GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 08. TUBERCULOSIS TREATMENT DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 09. TUBERCULOSIS TREATMENT DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. TUBERCULOSIS TREATMENT DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. TUBERCULOSIS TREATMENT DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 13. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 14. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 15. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 16. U.S. TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 17. U.S. TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 18. U.S. TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 19. CANADA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 20. CANADA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 21. CANADA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 22. MEXICO TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 23. MEXICO TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 24. MEXICO TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 25. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 26. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 27. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 28. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 29. GERMANY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 30. GERMANY TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 31. GERMANY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 32. FRANCE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 33. FRANCE TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 34. FRANCE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 35. UK TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 36. UK TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 37. UK TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 38. ITALY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 39. ITALY TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 40. ITALY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 41. SPAIN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 42. SPAIN TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 43. SPAIN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 44. REST OF EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 45. REST OF EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 46. REST OF EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 47. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 48. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 49. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 50. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 51. JAPAN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 52. JAPAN TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 53. JAPAN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 54. CHINA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 55. CHINA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 56. CHINA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 57. INDIA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 58. INDIA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 59. INDIA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 60. REST OF ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 61. REST OF ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 62. REST OF ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 63. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 64. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 65. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 66. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 67. LATIN AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 68. LATIN AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 69. LATIN AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 70. MIDDLE EAST AND AFRICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 71. MIDDLE EAST AND AFRICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
- TABLE 72. MIDDLE EAST AND AFRICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 73. LUPIN: KEY EXECUTIVES
- TABLE 74. LUPIN: COMPANY SNAPSHOT
- TABLE 75. LUPIN: PRODUCT SEGMENTS
- TABLE 76. LUPIN: PRODUCT PORTFOLIO
- TABLE 77. LUPIN: KEY STRATERGIES
- TABLE 78. MACLEODS PHARMACEUTICALS LTD.: KEY EXECUTIVES
- TABLE 79. MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
- TABLE 80. MACLEODS PHARMACEUTICALS LTD.: PRODUCT SEGMENTS
- TABLE 81. MACLEODS PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
- TABLE 82. SANOFI: KEY EXECUTIVES
- TABLE 83. SANOFI: COMPANY SNAPSHOT
- TABLE 84. SANOFI: PRODUCT SEGMENTS
- TABLE 85. SANOFI: PRODUCT PORTFOLIO
- TABLE 86. OTSUKA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
- TABLE 87. OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
- TABLE 88. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
- TABLE 89. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
- TABLE 90. OTSUKA PHARMACEUTICAL CO., LTD.: KEY STRATERGIES
- TABLE 91. PFIZER INC.: KEY EXECUTIVES
- TABLE 92. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 93. PFIZER INC.: PRODUCT SEGMENTS
- TABLE 94. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 95. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): KEY EXECUTIVES
- TABLE 96. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): COMPANY SNAPSHOT
- TABLE 97. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT SEGMENTS
- TABLE 98. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT PORTFOLIO
- TABLE 99. JOHNSON & JOHNSON: KEY EXECUTIVES
- TABLE 100. JOHNSON & JOHNSON: COMPANY SNAPSHOT
- TABLE 101. JOHNSON & JOHNSON: PRODUCT SEGMENTS
- TABLE 102. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
- TABLE 103. JOHNSON & JOHNSON: KEY STRATERGIES
- TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 106. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 107. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 108. NOVARTIS AG: KEY EXECUTIVES
- TABLE 109. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 110. NOVARTIS AG: PRODUCT SEGMENTS
- TABLE 111. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 112. ANI PHARMACEUTICALS, INC.: KEY EXECUTIVES
- TABLE 113. ANI PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
- TABLE 114. ANI PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
- TABLE 115. ANI PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
- TABLE 116. ANI PHARMACEUTICALS, INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031
- FIGURE 02. SEGMENTATION OF TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031
- FIGURE 03. TOP INVESTMENT POCKETS IN TUBERCULOSIS TREATMENT DRUGS MARKET (2022-2031)
- FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 05. LOW BARGAINING POWER OF BUYERS
- FIGURE 06. LOW THREAT OF SUBSTITUTES
- FIGURE 07. LOW THREAT OF NEW ENTRANTS
- FIGURE 08. LOW INTENSITY OF RIVALRY
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALTUBERCULOSIS TREATMENT DRUGS MARKET
- FIGURE 10. TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR ACTIVE TUBERCULOSIS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR LATENT TUBERCULOSIS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 13. TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR FIRST LINE THERAPY, BY COUNTRY 2021 AND 2031(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR SECOND LINE THERAPY, BY COUNTRY 2021 AND 2031(%)
- FIGURE 16. TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 20. TUBERCULOSIS TREATMENT DRUGS MARKET BY REGION, 2021
- FIGURE 21. U.S. TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 22. CANADA TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 23. MEXICO TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 24. GERMANY TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 25. FRANCE TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 26. UK TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 27. ITALY TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 28. SPAIN TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 29. REST OF EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 30. JAPAN TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 31. CHINA TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 32. INDIA TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 33. REST OF ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 34. LATIN AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 35. MIDDLE EAST AND AFRICA TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 39. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 40. COMPETITIVE DASHBOARD
- FIGURE 41. COMPETITIVE HEATMAP: TUBERCULOSIS TREATMENT DRUGS MARKET
- FIGURE 42. TOP PLAYER POSITIONING, 2021
- FIGURE 43. LUPIN: NET SALES, 2020-2022 ($MILLION)
- FIGURE 44. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 45. SANOFI: NET SALES, 2020-2022 ($MILLION)
- FIGURE 46. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 47. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 48. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 49. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 50. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 51. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 52. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 53. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 54. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
- FIGURE 55. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 56. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 57. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 59. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 60. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 61. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 62. ANI PHARMACEUTICALS, INC.: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 63. ANI PHARMACEUTICALS, INC.: REVENUE SHARE BY REGION, 2021 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook